Search - tctmd.com

Displaying 221 - 240 of 360

Sort: Relevancy | Date

News Daily News

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Michael O'Riordan

October 25, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Daily News

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Michael O'Riordan

October 18, 2018

News Daily News

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Michael O'Riordan

October 15, 2018

News Daily News

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Michael O'Riordan

October 08, 2018

News Conference News ESC 2018

ASCOT Legacy: Calcium Channel Blockers, Statins Confer Long-term Survival Benefits in Hypertensive Patients

L.A. McKeown

August 31, 2018

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

USPSTF: Insufficient Evidence to Support CAC Score, hsCRP, or ABI for Risk Assessment

Michael O'Riordan

July 12, 2018

News Daily News

Lp(a) Might Not Be Good at Predicting Incident CVD in Low-Risk Women

Yael L. Maxwell

July 09, 2018

News Daily News

Clinical Benefit of Lowering Lp(a) Is Proportional to Its Absolute Reduction: Mendelian Randomization Analysis

Yael L. Maxwell

June 25, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

News Conference News EAS 2018

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

Yael L. Maxwell

May 14, 2018

News Conference News EAS 2018

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Yael L. Maxwell

May 11, 2018

News Conference News EAS 2018

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Yael L. Maxwell

May 08, 2018

News Conference News EAS 2018

Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention

Yael L. Maxwell

May 07, 2018

News Daily News

LPA Variants Linked With CHD Events in Statin-Treated Patients

Michael O'Riordan

May 03, 2018

News Daily News

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Michael O'Riordan

April 20, 2018

Advertisement

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

ASCOT Legacy: Calcium Channel Blockers, Statins Confer Long-term Survival Benefits in Hypertensive Patients

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

USPSTF: Insufficient Evidence to Support CAC Score, hsCRP, or ABI for Risk Assessment

Lp(a) Might Not Be Good at Predicting Incident CVD in Low-Risk Women

Clinical Benefit of Lowering Lp(a) Is Proportional to Its Absolute Reduction: Mendelian Randomization Analysis

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention

LPA Variants Linked With CHD Events in Statin-Treated Patients

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content